Back to search results

Nicotinamide Riboside for Arterial Stiffness in Kidney Disease

This study is testing whether a supplement called Nicotinamide Riboside can help improve stiff arteries and high blood pressure in people with moderate to severe chronic kidney disease (CKD). Nicotinamide Riboside is a natural form of vitamin B3. Researchers want to see if this supplement can reduce the stiffness of your arteries, which is a common problem for people with CKD and can increase the risk of heart problems. To join, you need to be between 35 and 80 years old, have CKD stage III or IV (meaning your kidney function, measured by eGFR, is between 20-60 mL/min/1.73m2), and have controlled blood pressure. The study plans to enroll 118 participants, but its current status is unclear.

Study design
This is an interventional study planning to enroll 118 participants. It will compare Nicotinamide Riboside to another approach, though the specific comparison is not detailed.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your carotid-femoral pulse wave velocity (a measure of artery stiffness) will be checked at the beginning of the study and again after 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04040959

Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

Active, Not Recruiting
PHASE2Ages 35–80InterventionalTreatment
University of Colorado, Denver
~118 participants
Updated 2026-06-05 on ClinicalTrials.gov
What's tested:Nicotinamide riboside

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
carotid-femoral pulse wave velocity
Measured over Baseline and 3 months

Conditions

Vascular Diseases
Kidney Disease
Blood Pressure
Oxidative Stress

Explore related trials

Chronic Kidney DiseaseHypertension

NCT04040959

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UColorado

    Aurora, Coloradono site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Michel Chonchol, MD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 35-80 years;
Ability to provide informed consent;
Willing to accept random assignment to condition;
CKD stage III or IV (eGFR with the 4-variable MDRD prediction equation: 20-60 mL/min/1.73m2; stable renal function in the past 3 months);
Blood pressure controlled to \<140/90 mmHg for the past 3 months;
Body mass index \<40 kg/m2;
Weight stable in the prior 3 months (\<2 kg weight change) and willing to remain weight stable throughout the study

Exclusion

Patients with advanced CKD requiring chronic dialysis;
Significant co-morbid conditions that lead the investigator to conclude that life expectancy \< 1 year;
History of severe congestive heart failure (i.e., ejection fraction \< 35%);
Hospitalization in the past month;
Proteinuria \> 5 g/day;
Immunosuppressant agents such as cyclosporine, tacrolimus, azathioprine, etanercept, infliximab, adalimumab, anakinra or long-term oral glucocorticoids taken in past 12 months;
Known malignancy;
Woman who are pregnant, nursing or planning to become pregnant;
Special classes of subjects considered vulnerable populations will not be included in the study.

What this trial measures

  • carotid-femoral pulse wave velocityBaseline and 3 months

    change in carotid-femoral pulse wave velocity